


10-1-2013

## Sevoflurane confers additive cardioprotection to ethanol preconditioning associated with enhanced phosphorylation of glycogen synthase kinase-3 $\beta$ and inhibition of mitochondrial permeability transition pore opening.

Anna Onishi  
*Osaka Dental University*

Masami Miyamae  
*Osaka Dental University*

Hiroshi Inoue  
*Osaka Dental University*  
Osaka Dental University digital works at: <https://jdc.jefferson.edu/cardiologypf>

 Part of the [Cardiology Commons](#)  
Kazuhiko Kaneda  
*Osaka Dental University*

[Let us know how access to this document benefits you](#)

Chika Okusa

*Osaka Dental University*

### Recommended Citation

Onishi, Anna; Miyamae, Masami; Inoue, Hiroshi; Kaneda, Kazuhiro; Okusa, Chika; Inamura, Yoshitaka; Shiomi, Mayumi; Koshinuma, Shizuka; Momota, Yoshihiro; and Figueredo, Vincent M.,  
*See next page for additional authors*  
"Sevoflurane confers additive cardioprotection to ethanol preconditioning associated with enhanced phosphorylation of glycogen synthase kinase-3 $\beta$  and inhibition of mitochondrial permeability transition pore opening." (2013). *Division of Cardiology Faculty Papers*. Paper 30.  
<https://jdc.jefferson.edu/cardiologypf/30>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Division of Cardiology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [JeffersonDigitalCommons@jefferson.edu](mailto:JeffersonDigitalCommons@jefferson.edu).

---

## Authors

Anna Onishi, Masami Miyamae, Hiroshi Inoue, Kazuhiro Kaneda, Chika Okusa, Yoshitaka Inamura, Mayumi Shiomi, Shizuka Koshinuma, Yoshihiro Momota, and Vincent M. Figueredo

As submitted to:

*Journal of cardiothoracic and vascular anesthesia.*

And later published as:

Sevoflurane Confers Additive Cardioprotection to Ethanol  
Preconditioning Associated with Enhanced Phosphorylation of  
Glycogen Synthase Kinase 3 $\beta$  and Inhibition of Mitochondrial  
Permeability Transition Pore Opening

Volume 27, Issue 5, October 2013, pp. 916-24.

DOI: 10.1053/j.jvca.2012.10.002

Anna Onishi, DDS, PhD\*, Masami Miyamae, MD, PhD<sup>†</sup>, Hiroshi Inoue, DDS, PhD<sup>#</sup>,  
Kazuhiro Kaneda, DDS, PhD\*, Chika Okusa, DDS, PhD\*, Yoshitaka Inamura, DDS, PhD\*,  
Mayumi Shiomi, MD<sup>&</sup>, Shizuka Koshinuma, DDS\*, Yoshihiro Momota, DDS, PhD<sup>£</sup>, Vincent  
M. Figueredo, MD<sup>¶</sup>

\*Postdoctoral Researcher, <sup>£</sup>Assistant Professor, Department of Anesthesiology, <sup>†</sup>Associate  
Professor, Department of Internal Medicine, <sup>#</sup>Assistant Professor, Department of Physiology,  
Osaka Dental University, <sup>&</sup>Postdoctoral Researcher, Department of Anesthesiology, Osaka  
Medical College, Osaka, Japan, <sup>¶</sup>Professor, Institute for Heart and Vascular Health, Albert  
Einstein Medical Center, and Jefferson Medical College, Philadelphia, USA

Corresponding Author & Reprints: Masami Miyamae, MD, PhD  
Department of Internal Medicine,

Osaka Dental University  
8-1 Kuzuha hanazono-cho Hirakata,  
Osaka 573-1121, Japan  
TEL: 81-72-864-3079, FAX: 81-72-864-3179  
E-mail: miyamae0907@gmail.com

This work was supported by Grant-in-Aid for Research Activity Start-up (Grant No. 24890153 to A.O.) and Scientific Research (C) (Grant No. 20592382 to M.M.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (Tokyo, Japan).

## ABSTRACT

Objective: The purpose of this study was to investigate whether sevoflurane enhances moderate dose ethanol preconditioning, and whether this additional cardioprotection is associated with glycogen synthase kinase 3 $\beta$  (GSK3 $\beta$ ), Akt, mammalian target of rapamycin (mTOR), 70-KDa ribosomal s6 kinase 1 (p70s6K), and/or mitochondrial permeability transition pore (MPTP) opening.

Design: In vitro study using an isolated heart Langendorff preparation.

Setting: University research laboratory.

Participants: Male guinea pigs (n=170).

Interventions: Isolated perfused guinea pig hearts underwent 30 min ischemia and 120 min reperfusion (control:CTL). The ethanol group (EtOH) received 5% ethanol in their drinking water for 8 weeks. Anesthetic preconditioning was elicited by 10 min exposure to sevoflurane (2%) in ethanol (EtOH+SEVO) or non-ethanol (SEVO) hearts. Inhibition of GSK3 $\beta$  phosphorylation and mTOR was achieved with LY294002 and rapamycin, respectively. GSK3 $\beta$ , Akt, mTOR and p70s6K expression were determined by Western blot. Calcium-induced MPTP opening was assessed in isolated calcein-loaded mitochondria.

Measurements and Main Results: After ischemia-reperfusion, EtOH, SEVO and EtOH+SEVO had higher left ventricular developed pressure recovery and lower end-diastolic pressure versus CTL. Infarct size was reduced in EtOH and SEVO versus CTL. EtOH+SEVO further reduced infarct size. Phosphorylation of GSK3 $\beta$  and Akt, but not mTOR and p70s6K, was increased in EtOH and SEVO. Phosphorylation of GSK3 $\beta$ , but not mTOR and p70s6K was further increased in EtOH+SEVO. EtOH and SEVO reduced calcium-induced MPTP opening. EtOH+SEVO further reduced MPTP opening.

*Conclusions:* Sevoflurane and chronic ethanol preconditioning offer additive cardioprotection. This effect is associated with enhanced GSK3 $\beta$  phosphorylation and inhibition of MPTP opening.

Key words: sevoflurane, preconditioning, ethanol, glycogen synthase kinase 3 $\beta$ , mitochondrial permeability transition pore

## INTRODUCTION

Epidemiological studies have shown that mortality rates for people who regularly drink ethanol in moderation are lower than in abstainers, primarily due to decreased fatal ischemic heart disease.<sup>1</sup> Further, moderate ethanol consumers have lower rates of myocardial infarction compared with abstainers.<sup>2</sup> These beneficial cardiac effects may be due to pleiotropic effects of ethanol on lipids,<sup>3</sup> platelets, and fibrinolytic activity.<sup>4,5</sup> In addition, experimental studies have revealed that light to moderate regular ethanol consumption renders hearts more tolerant to ischemia-reperfusion injury (ethanol preconditioning)<sup>6-12</sup>, similar to ischemic preconditioning<sup>13</sup> in which brief episodes ischemia and reperfusion dramatically limit infarct size following prolonged ischemia. A recent study suggests that light to moderate regular ethanol consumption in the year prior to myocardial infarction is associated with reduced mortality following myocardial infarction.<sup>14</sup> These findings suggest that light to moderate ethanol consumption not only prevents myocardial infarction but also improves survival after myocardial infarction.

Over the last 15 years, experimental and clinical studies have indicated that the use of volatile anesthetics constitutes an additional therapeutic approach in the care of patients at risk of developing perioperative cardiac complications, known as volatile anesthetic preconditioning.<sup>15</sup> It has been shown that preconditioned myocardium can also be protected by pharmacological agents such as erythropoietin,<sup>16</sup> volatile anesthetics<sup>17</sup> and ethanol.<sup>18,19</sup> We previously demonstrated that regular ethanol consumption renders hearts more tolerant to ischemia-reperfusion injury, to a degree similar to acute ischemic preconditioning.<sup>6</sup> We also reported that sevoflurane enhances low dose (2.5%) ethanol-induced preconditioning through modulation of protein kinase C (PKC), mitochondrial K<sub>ATP</sub> channels (mitoK<sub>ATP</sub>) and

endothelial nitric oxide synthase (eNOS).<sup>18</sup> However, whether sevoflurane exerts enhanced cardioprotection at higher, clinically relevant, ethanol doses (e.g. 5%) is unknown. Furthermore, the precise mechanisms which ultimately confer this additive cardioprotection have not been elucidated. Growing evidence suggests that many cardioprotective signaling pathways converge on the mitochondria to reduce cell death.<sup>20-22</sup> Mitochondrial permeability transition pore (MPTP) opening has been proposed as a crucial determinant of ischemia-reperfusion injury.<sup>23</sup>

Ge et al. demonstrated that prevention of MPTP opening by isoflurane postconditioning is eNOS dependent.<sup>24</sup> Interestingly, chronic ethanol exposure has been shown to increase eNOS expression.<sup>18</sup>

Studies have shown that inactivation of glycogen synthase kinase 3 $\beta$  (GSK3 $\beta$ ) by phosphorylation at Ser<sup>9</sup> inhibits MPTP opening and protects cardiomyocytes.<sup>25,26</sup> GSK3 $\beta$  is inactivated by phosphatidylinositol 3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR)/p70s6K pathways.<sup>27</sup> Neznanova et al.<sup>28</sup> reported that acute ethanol challenge phosphorylates GSK3 $\beta$  in the rat prefrontal cortex. Zhou et al.<sup>29</sup> demonstrated that acute ethanol exposure to H9c2 cardiac cells prevents oxidant-induced MPTP opening through inactivation of GSK3 $\beta$ . Inhibition of GSK3 $\beta$  has been also implicated in volatile anesthetic postconditioning.<sup>30-32</sup>

These data suggest that the additive effect of sevoflurane and ethanol preconditioning could be mediated by enhanced inhibition of MPTP opening. To date, the roles of the Akt/GSK3 $\beta$  and mTOR/p70s6K pathways in cardioprotection induced by chronic ethanol exposure has not been studied. Thus, we hypothesized that sevoflurane enhances moderate dose (5%) ethanol-induced preconditioning and this additive cardioprotection is associated

with 1) enhanced GSK3 $\beta$  inactivation, 2) Akt, mTOR or p70s6K activation and/or 3) enhanced inhibition of MPTP opening. Elucidating mechanisms underlying the additive cardioprotection of ethanol and sevoflurane could lead to a drug discovery to further reduce perioperative myocardial ischemia-reperfusion injury.

## METHODS

This study was conducted in accordance with the Guidelines for Animals Research and with the approval of the Animal Experiment Committee of Osaka Dental University, Osaka, Japan. These guidelines conform to those laid out in the Guide for the Care and Use of Laboratory Animals, available from the National Academy of Science.<sup>33</sup> Male Hartley guinea pigs were fed Lab Diet (RC4, Oriental Yeast, Tokyo, Japan) and given water *ad libitum*.

Male guinea pigs weighing 300-350g (3-4 weeks old) were initially given 1.25% ethanol in their drinking water for 1 week, 2.5% for 1 week then 5% for 8 weeks (ethanol group: EtOH). Control group was treated with drinking water for 10 weeks (CTL). After treatment, animals (550-700g, 13-14 weeks old) were given heparin (1000 units intraperitoneally), then anesthetized with pentobarbital (60 mg/kg, intraperitoneally). Hearts were excised and immediately arrested in cold iso-osmotic saline containing 20 mM KCl. The aorta was cannulated and the isolated hearts were perfused at 70 mmHg on a nonrecirculating isovolumic perfused heart apparatus, using a Krebs-Henseleit perfusate and paced at 240 beats/min as previously described.<sup>32</sup> Serum ethanol levels at time of sacrifice were measured by gas chromatography (Shimadzu, Kyoto, Japan). Liver enzymes were measured to rule out possible liver tissue damage. Sevoflurane was insufflated by passing the 95%O<sub>2</sub>/5%CO<sub>2</sub> gas mixture through a calibrated vaporizer (ACOMA, Tokyo, Japan). Samples of coronary perfusate were collected anaerobically from the aortic cannula for measurement of sevoflurane concentration by an organic vapor sensor (OSP, Saitama, Japan).

Animals were assigned to one of 8 groups (n=8 each; Figure 1). After a 20 min equilibration, baseline left ventricular developed (LVDP; mmHg) and end-diastolic (LVEDP; mmHg) pressures, and coronary flow (CF;  $\text{ml} \cdot \text{min}^{-1} \cdot \text{g}^{-1}$ ) were recorded. Control and EtOH groups were subjected to 30 min of ischemia followed by 120 min of reperfusion. Anesthetic preconditioning was elicited by administration of sevoflurane (2%) for 10 min followed by 10 min washout before 30 min of ischemia followed by 120 min of reperfusion (SEVO). To investigate whether sevoflurane enhances ethanol preconditioning, ethanol-treated hearts were subjected to the identical protocol of SEVO group (EtOH+SEVO).

To investigate the role of GSK3 $\beta$ , its upstream, PI3K inhibitor, LY294002 (Cayman Chemical, Ann Arbor, MI) or saline as a vehicle were administered starting 5 min before sevoflurane exposure and throughout the reperfusion period in EtOH, SEVO, EtOH+SEVO and CTL groups (EtOH+LY, SEVO+LY, EtOH+SEVO+LY, CTL+LY). LY294002 was dissolved in ethanol (0.03%), and added to the KH perfusate to a final concentration of 15  $\mu\text{M}$ . To investigate the involvement of mTOR and p70s6K in EtOH hearts treated with sevoflurane, rapamycin (100nM, Sigma ALDRICHI, St. Louis, MO) or saline as a vehicle were administered starting 5 min before sevoflurane exposure and throughout the reperfusion period in CTL and EtOH+SEVO groups (CTL+Rapa, EtOH+SEVO+Rapa). These doses of LY294002 and rapamycin were previously reported to effectively inhibit PI3K and mTOR, respectively.<sup>34,35</sup> We performed experiments in the following order (with the laboratory investigator performing the experiments blinded to the groups): first a CTL, followed by ETOH, SEVO, ETOH+SEVO, and so forth until the first series of experiments were completed. The experiments using LY294002 and rapamycin were done in the same manner.

At the end of experiments, the hearts were quickly frozen at  $-80^{\circ}\text{C}$  for 15 min, then sliced into 2 mm thick transverse sections from apex to base (6 slices/heart). Each slice was weighed and incubated at  $37^{\circ}\text{C}$  with 1% triphenyltetrazolium chloride (Sigma ALDRICH) in phosphate buffer (pH 7.4) for 10 min and then fixed in 10% formalin for at least 5 h to distinguish red stained viable tissue from pale unstained necrotic tissue.<sup>36</sup> Infarct size was determined using Adobe Photoshop<sup>®</sup> CS4 (Adobe, San Jose, USA) as previously described.<sup>32</sup>

Separate experiments were performed ( $n=4$  in each group) to examine expression of Akt, mTOR, p70s6K and GSK3 $\beta$ . For this purpose, different hearts from infarct size study were used. Myocardial tissue samples were collected at 5 min after reperfusion, and homogenized in ice-cold homogenizing buffer with protein samples and membranes prepared as previously described.<sup>32</sup> After blocking with 5% skim milk in Tris-buffered saline containing 0.1% Tween-20 (TBS-T), the membranes were incubated for 2 h at  $4^{\circ}\text{C}$  in TBS-T containing 5% milk and overnight 1:500-1000 dilution of rabbit primary antibody for phospho Akt (Ser47), mTOR (Ser2448), p70s6K (Thr389) and GSK3 $\beta$  (Ser9) (Cell Signaling TECHNOLOGY, Boston, USA). Membranes were incubated with a 1:1000 dilution of horseradish peroxidase-labeled anti-rabbit immunoglobulin G (NA 934V, GE Healthcare, Buckinghamshire, UK). The same blot was stripped and re-blotted with antibodies to  $\alpha$ -tubulin (to confirm equal protein loading), total Akt, mTOR, p70s6K and GSK3 $\beta$  (Cell Signaling TECHNOLOGY). Bound antibody signals were detected with enhanced chemiluminescence (Pierce Biotechnology, Rockford, USA) and visualized using VersaDoc 5000 Imaging System (Bio-Rad, Hercules, USA). Quantitative analysis of the band densities was performed by Quantity One software (Bio-Rad) as previously

described.<sup>37</sup>

To investigate the involvement of MPTP in enhanced cardioprotection, mitochondria were isolated from guinea pig hearts (n=4 for each group). For this purpose, different hearts from infarct size study were used. After perfused and exposed to sevoflurane and inhibitors, isolated hearts were removed from the Langendorff apparatus and homogenized in ice-cold MSTEB buffer as previously described.<sup>37</sup> The extracted mitochondria were diluted in ice-cold respiratory buffer and incubated with 1  $\mu$ M calcein-AM (Invitrogen Molecular Probes, Carlsbad, USA) for 15 min at room temperature. Calcein-AM readily enters the mitochondria and is trapped in the matrix in its free form, which is fluorescent. After calcein was trapped in mitochondria, the mitochondria were washed by KCl buffer as previously described.<sup>37</sup> Calcein-loaded mitochondria were treated with 50 and 150  $\mu$ M  $\text{Ca}^{2+}$  per milligram of protein, and were incubated for 10 min at room temperature. Then mitochondrial fluorescences were acquired. Flow cytometric analysis was performed on FACS caliber™ (Becton Dickinson, Franklin lakes, USA). Mitochondria labeled with calcein-AM were analyzed by flow cytometry in an instrument equipped with a 488 nm excitation source.

Statistical power analysis revealed that a sample size of n=8 would provide sufficient power (0.8) to detect a difference between mean infarct size indices of 15 % (SD=9,  $\alpha=0.05$ ). A group size of n=4 was used for Western blot and calcein studies to provide a power of 0.8 to detect a difference between means of 20% (SD=10,  $\alpha=0.05$ ). Hemodynamic data were tested for normal distribution and subsequently analyzed by a two-factor repeated-measures analysis of variance for time and treatment. If an overall difference between the variables was observed, comparisons were performed as one-way ANOVA followed by Tukey's post-

hoc test for inter-group differences and by Dunnett's for intra-group differences with baseline values as the reference time point. Analysis of infarct size, Western blot and mitochondrial calcein fluorescence was performed using one-way ANOVA followed by Student's t-test with Bonferroni's correction for multiple comparisons to avoid type I error. For changes within and between groups a two-tailed p value less than 0.05 was considered significant in advance. (SPSS17 for Windows, SPSS Japan, Tokyo, Japan).

## RESULTS

Of a total of 170, 10 hearts were not used secondary to intractable ventricular fibrillation after reperfusion (mortality rate was not different among groups) and one heart was not used due to aortic rupture. Additional hearts were studied until each group had  $n=8$  successful experiments. There was no significant difference in body weight among groups. Serum ethanol level at time of sacrifice was  $3.5\pm 2.7$  mM. As a comparison, the minimum blood alcohol concentration associated with intoxication in humans is 8 mM (40 mg/dl or 0.04%). Ethanol was not detected in the effluent of the 10 EtOH hearts sampled after 50 min washout. There was no difference in liver enzymes levels between EtOH and CTL animals. The concentration of sevoflurane in the coronary perfusate after 10 min of exposure was  $0.27\pm 0.02$  mM.

Myocardial infarct size in EtOH and SEVO were significantly reduced compared with CTL (EtOH:  $24\pm 8\%$ , SEVO:  $23\pm 6\%$  vs. CTL:  $41\pm 6\%$ ,  $p<0.05$ ). The administration of sevoflurane in EtOH hearts further decreased infarct size compared with EtOH alone (EtOH+SEVO:  $10\pm 4\%$ , vs. EtOH:  $24\pm 8\%$ ,  $p<0.05$ ). This reduction of myocardial infarct size in EtOH+SEVO was abolished by LY294002, but not by rapamycin (EtOH+SEVO+LY:  $31\pm 3\%$ ,  $p=0.188$ , EtOH+SEVO+Rapa:  $17\pm 5\%$ ,  $p<0.05$ , vs. CTL). Treatment with LY294002 alone did not affect the infarct size compared with CTL, though treatment with rapamycin alone did reduce infarct size (CTL+Rapa:  $27\pm 9\%$ ,  $p<0.05$ , vs. CTL) (Fig 2).

Baseline LVDP and CF were similar among the 8 groups. Administration of sevoflurane or treatment with LY294002 and rapamycin did not significantly affect LVDP or CF before ischemia. After 120 min reperfusion, recovery of LVDP was greater in EtOH,

SEVO, EtOH+SEVO and CTL+Rapa compared with CTL. Recovery of LVDP in EtOH+SEVO hearts was abolished by administration of LY294002, but not rapamycin. Treatment with LY294002 or rapamycin alone did not adversely affect recovery of LVDP. LVEDP increased to 600% of baseline in CTL after ischemia-reperfusion. The increase in LVEDP was significantly less in EtOH, SEVO, EtOH+SEVO and CTL+Rapa compared with CTL. Of note, LVEDP in LY294002 treated groups was lower compared with CTL, but not compared with EtOH, SEVO or EtOH+SEVO. There was no significant difference in CF among all groups throughout the experiment. This suggests that changes in CF could not account for the improved contractile recovery of EtOH, SEVO, ETOH+SEVO hearts (Table 1).

Total Akt and GSK3 $\beta$  were comparable in all samples. The ratio of phospho Akt to total Akt and phospho GSK3 $\beta$  to total GSK3 $\beta$  was significantly increased in EtOH and SEVO compared with CTL. This increase was not caused by unequal loading of the western blot, as shown by the detection of  $\alpha$ -tubulin. The combination of ethanol and sevoflurane enhanced this increased expression of phospho GSK3 $\beta$  in EtOH+SEVO. Administration of LY294002, but not rapamycin, abolished this enhanced expression of phospho GSK3 $\beta$  in EtOH+SEVO. Treatment with rapamycin alone increased phospho Akt and phospho GSK3 $\beta$  expressions. The ratio of phospho mTOR to total mTOR and phospho p70s6K to total p70s6K was not increased in CTL, EtOH and SEVO. However, it was significantly increased in EtOH+SEVO compared with other groups. This increase was abolished by rapamycin (Fig 3).

The mitochondrial calcein fluorescence values after treatment with Ca<sup>2+</sup> were taken as the values from which any reduction in fluorescence was measured. Exposure of

mitochondria to 50  $\mu\text{M}$   $\text{Ca}^{2+}$  did not induce MPTP opening in any groups (Fig 4A). However, exposure of mitochondria to 150 $\mu\text{M}$   $\text{Ca}^{2+}$  induced MPTP opening, represented by a reduction in calcein fluorescence of  $-59.3 \pm 12.1\%$  in CTL. This  $\text{Ca}^{2+}$ -induced reduction was attenuated in EtOH and SEVO ( $-37.9 \pm 11.9\%$ ;  $p < 0.05$ ,  $-26.9 \pm 8.1\%$ ;  $p < 0.05$ , respectively, vs. CTL) (Fig 4B). This effect was enhanced by the combination of ethanol and sevoflurane (EtOH+SEVO:  $-3.0 \pm 9.9\%$ ;  $p < 0.05$  vs. EtOH and SEVO), which was abrogated by treatment with LY294002 ( $-60.4 \pm 9.3\%$ ), but not rapamycin ( $-16.4 \pm 19.2\%$ ;  $p < 0.05$  vs. CTL). Treatment with rapamycin alone slightly attenuated reductions in fluorescence of CTL, but this effect did not reach statistical significance (CTL+Rapa:  $-48.5 \pm 9.4\%$ ) (Fig 4C).

## DISCUSSION

Sevoflurane confers additive cardioprotection to moderate dose ethanol-induced preconditioning. Further, this cardioprotective effect is associated with enhanced phosphorylation/inhibition of GSK3 $\beta$  and inhibition of MPTP opening. We previously demonstrated that exposure to 2.5% (low dose) ethanol for 6 weeks reduces ischemia-reperfusion injury to the same degree as 5%, 10%, and 20% ethanol for 6 to 12 weeks.<sup>6</sup> We also found that sevoflurane enhances low dose ethanol-induced preconditioning.<sup>18</sup> The present study suggests that sevoflurane enhances cardioprotection afforded by ethanol preconditioning at a higher level of exposure, equivalent to moderate ethanol consumption. It has been reported that the combination of two preconditioning stimuli enhances cardioprotection afforded by either stimulus alone.<sup>16,18,19,38</sup> The present study demonstrated that the combination of moderate ethanol consumption and sevoflurane exposure enhanced inhibition of MPTP opening associated with enhanced GSK3 $\beta$  phosphorylation through both PI3K-Akt and mTOR/p70s6K pathways.

Nishihara et al.<sup>16</sup> demonstrated that erythropoietin affords additional cardioprotection to ischemic preconditioning by enhanced phosphorylation of GSK3 $\beta$  in *in vivo* rabbit hearts, but involvement of MPTP opening was not investigated. Zhou et al.<sup>29</sup> demonstrated that acute ethanol exposure to H9c2 cardiac cells prevented oxidant-induced MPTP opening through inactivation of GSK3 $\beta$ .

It is now widely recognized that MPTP opening is a major cause of myocardial cell death after reperfusion and a target for cardioprotection.<sup>21</sup> Under physiological conditions, MPTP is predominantly in a closed state. The opening of MPTP is increased by calcium overload due to ischemia, ATP depletion, accumulation of inorganic phosphate and burst

production of reactive oxygen species (ROS) immediately after reperfusion. This MPTP opening results in depolarization of the mitochondrial membrane potential and matrix swelling.<sup>39,40</sup> Although acute ethanol exposure to H9c2 cardiac cells has been shown to prevent ROS-induced MPTP opening,<sup>29</sup> whether chronic ethanol consumption prevents calcium-induced MPTP opening has not been investigated. The present study addressed the susceptibility of MPTP opening after  $\text{Ca}^{2+}$  loading in isolated mitochondria from hearts that were chronically exposed to moderate ethanol. Furthermore, acute sevoflurane exposure to ethanol-treated mitochondria enhanced the inhibition of MPTP opening. Exposure of mitochondria to  $150\ \mu\text{M}\ \text{Ca}^{2+}$ , not  $50\ \mu\text{M}\ \text{Ca}^{2+}$ , induced MPTP opening in control hearts, represented by reduction in calcein fluorescence. This reduction was attenuated in mitochondria from ethanol and sevoflurane exposed hearts, and to an even greater degree in mitochondria from hearts exposed to both moderate ethanol and sevoflurane.

The threshold for MPTP opening is elevated by phosphorylation of GSK3 $\beta$  at Ser<sup>9</sup>, which inactivates this kinase.<sup>26</sup> In turn, GSK3 $\beta$  has been shown to be inactivated by PI3K/Akt and mTOR/p70s6K pathways.<sup>27</sup> In the present study, ethanol or sevoflurane alone increased GSK3 $\beta$  phosphorylation through Akt activation, but not mTOR/p70s6K. Interestingly, the combination of ethanol and sevoflurane activated both pathways, leading to enhanced phosphorylation of GSK3 $\beta$ . The role of mTOR in cardioprotection remains controversial. Studies have demonstrated a protective effect of rapamycin, an mTOR inhibitor.<sup>41</sup> A recent study demonstrated that cardioprotection by ischemic preconditioning involves both mTOR and Wnt pathways, placing mTOR downstream of GSK3 $\beta$ .<sup>42</sup> In the present study, phosphorylation of both GSK3 $\beta$  and mTOR was seen in only EtOH+SEVO, which was abolished by LY294002. This suggests that PI3K/Akt and GSK3 $\beta$  are important

mediators of this additive cardioprotection. Rapamycin failed to abolish the enhanced inhibition of MPTP opening and reduction of infarct size in EtOH+SEVO. However, rapamycin has been shown to protect the heart against ischemia-reperfusion injury through Akt activation.<sup>35,41</sup> This is consistent with the present study as seen in CTL+Rapa group. The combination of EtOH and sevoflurane may activate additional cardioprotective signaling pathways and mTOR may not be essential for inhibition of MPTP. The exact relationship between GSK3 $\beta$  and mTOR remains unclear, as there is currently no drug available to directly inhibit phosphorylation/inactivation of GSK3 $\beta$ . mTOR consists of two functionally distinct complexes, that is, mTOR complex 1 and complex 2. A component of mTOR complex 2, Rictor (rapamycin-insensitive associated protein of mTOR) has been implicated in activating cell survival.<sup>43</sup> Recently, ethanol has been shown to increase the activity of mTOR complex 2 in myoblast.<sup>44</sup> The potential mechanisms of enhanced cardioprotection by the combination of ethanol and sevoflurane found in this study are summarized in Figure 5.

The following study limitations should be acknowledged. First, in order to more fully mimic the clinical setting, sevoflurane should be administered throughout experiments. However, our previous study has shown that a brief exposure to the heart is as effective as continued administration of sevoflurane.<sup>32</sup> Second, we utilized isolated mitochondria exposed to high concentrations of Ca<sup>2+</sup> to evaluate MPTP opening susceptibility in vitro. A previous study demonstrated that the amount of Ca<sup>2+</sup> required to induce MPTP opening depends on the experimental conditions such as the presence of adenine nucleotides in the medium.<sup>45</sup> Although we cannot rule out the possibility that our results may not accurately reflect the conditions experienced by in vivo mitochondria during ischemia-reperfusion,<sup>46</sup> our primary purpose was to assess the susceptibility of MPTP opening in isolated mitochondria exposed

to ethanol and sevoflurane. Third, GSK3 $\beta$  is a substrate for multiple pro-survival protein kinases, including Akt,  $\epsilon$ -PKC, extracellular signal-regulated kinase 1/2 and protein kinase G<sup>27</sup>. We cannot exclude the possibility that kinases other than PI3K/Akt and mTOR/p70s6K pathways may contribute to enhanced phosphorylation of GSK3 $\beta$  by ethanol and sevoflurane. Fourth, Krenz et al. demonstrated that acute (as opposed to chronic) ethanol exposure fails to exert cardioprotection when ethanol is present during ischemia-reperfusion.<sup>47</sup> Although not withdrawn from the drinking water before sacrifice in the present study, serum ethanol levels were low (3.5 mM) at the time of sacrifice, and no ethanol was present in the perfusate at the time of ischemia-reperfusion.

In conclusion, sevoflurane enhances cardiac preconditioning induced by moderate, as well as, low dose ethanol consumption. This effect may be mediated by preventing MPTP opening through convergence of protective signaling on GSK3 $\beta$  phosphorylation/inhibition. Because volatile anesthetics can be administered with relatively low toxicity, elucidating the mechanisms underlying ethanol and volatile anesthetic-induced preconditioning could hopefully lead to therapies to reduce perioperative myocardial ischemia-reperfusion injury.

## REFERENCES

1. Klatsky AL, Armstrong MA, Friedman GD: Risk of cardiovascular mortality in alcohol drinkers, ex-drinkers and nondrinkers. *Am J Cardiol* 66:1237-1242, 1990
2. Mukamal KJ, Maclure M, Muller JE, et al.: Prior alcohol consumption and mortality following acute myocardial infarction. *Jama* 285:1965-1970, 2001
3. Gaziano JM, Buring JE, Breslow JL, et al.: Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. *N Engl J Med* 329:1829-1834, 1993
4. Pikaar NA, Wedel M, van der Beek EJ, et al.: Effects of moderate alcohol consumption on platelet aggregation, fibrinolysis, and blood lipids. *Metabolism* 36:538-543, 1987
5. Ridker PM, Vaughan DE, Stampfer MJ, et al.: Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. *Jama* 272:929-933, 1994
6. Miyamae M, Diamond I, Weiner MW, et al.: Regular alcohol consumption mimics cardiac preconditioning by protecting against ischemia-reperfusion injury. *Proc Natl Acad Sci U S A* 94:3235-3239, 1997
7. Miyamae M, Rodriguez MM, Camacho SA, et al.: Activation of  $\epsilon$  protein kinase C correlates with a cardioprotective effect of regular ethanol consumption. *Proc Natl Acad Sci U S A* 95:8262-8267, 1998
8. Miyamae M, Camacho SA, Zhou HZ, et al.: Alcohol consumption reduces ischemia-reperfusion injury by species-specific signaling in guinea pigs and rats. *Am J Physiol* 275:H50-56, 1998

9. Miyamae M, Domae N, Zhou HZ, et al.: Phospholipase C activation is required for cardioprotection by ethanol consumption. *Exp Clin Cardiol* 8:184-188, 2003
10. Miyamae M, Kaneda K, Domae N, et al.: Cardioprotection by regular ethanol consumption: potential mechanisms and clinical application. *Curr Drug Abuse Rev* 3:39-48, 2010
11. Pagel PS, Krolikowski JG, Kehl F, et al.: The role of mitochondrial and sarcolemmal K(ATP) channels in canine ethanol-induced preconditioning in vivo. *Anesth Analg* 94:841-848, 2002
12. Gross ER, Gare M, Toller WG, et al.: Ethanol enhances the functional recovery of stunned myocardium independent of K(ATP) channels in dogs. *Anesth Analg* 92:299-305, 2001
13. Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation* 74:1124-1136, 1986
14. Janszky I, Ljung R, Ahnve S, et al.: Alcohol and long-term prognosis after a first acute myocardial infarction: the SHEEP study. *Eur Heart J* 29:45-53, 2008
15. De Hert SG: Anesthetic preconditioning: how important is it in today's cardiac anesthesia? *J Cardiothorac Vasc Anesth* 20:473-476, 2006
16. Nishihara M, Miura T, Miki T, et al.: Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 $\beta$ . *Am J Physiol Heart Circ Physiol* 291:H748-755, 2006
17. Kersten JR, Schmeling TJ, Pagel PS, et al.: Isoflurane mimics ischemic preconditioning via activation of K(ATP) channels: reduction of myocardial infarct size with an acute memory phase. *Anesthesiology* 87:361-370, 1997

18. Kaneda K, Miyamae M, Sugioka S, et al.: Sevoflurane enhances ethanol-induced cardiac preconditioning through modulation of protein kinase C, mitochondrial KATP channels, and nitric oxide synthase, in guinea pig hearts. *Anesth Analg* 106:9-16., 2008
19. Guiraud A, de Lorgeil M, Boucher F, et al.: Cardioprotective effect of chronic low dose ethanol drinking: insights into the concept of ethanol preconditioning. *J Mol Cell Cardiol* 36:561-566, 2004
20. Hausenloy DJ, Yellon DM: Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. *Heart Fail Rev* 12:217-234, 2007
21. Garlid KD, Costa AD, Quinlan CL, et al.: Cardioprotective signaling to mitochondria. *J Mol Cell Cardiol* 46:858-866, 2009
22. Zaugg M, Lucchinetti E, Spahn DR, et al.: Volatile anesthetics mimic cardiac preconditioning by priming the activation of mitochondrial K(ATP) channels via multiple signaling pathways. *Anesthesiology* 97:4-14, 2002
23. Halestrap AP, Clarke SJ, Javadov SA: Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. *Cardiovasc Res* 61:372-385, 2004
24. Ge ZD, Pravdic D, Bienengraeber M, et al.: Isoflurane postconditioning protects against reperfusion injury by preventing mitochondrial permeability transition by an endothelial nitric oxide synthase-dependent mechanism. *Anesthesiology* 112:73-85, 2010
25. Tong H, Imahashi K, Steenbergen C, et al.: Phosphorylation of glycogen synthase kinase-3 $\beta$  during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. *Circ Res* 90:377-379, 2002

26. Juhaszova M, Zorov DB, Kim SH, et al.: Glycogen synthase kinase-3 $\beta$  mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. *J Clin Invest* 113:1535-1549, 2004
27. Cohen P, Frame S: The renaissance of GSK3. *Nat Rev Mol Cell Biol* 2:769-776, 2001
28. Neznanova O, Björk K, Rimondini R, et al.: Acute ethanol challenge inhibits glycogen synthase kinase-3 $\beta$  in the rat prefrontal cortex. *Int J Neuropsychopharmacol* 12:275-280, 2009
29. Zhou K, Zhang L, Xi J, et al.: Ethanol prevents oxidant-induced mitochondrial permeability transition pore opening in cardiac cells. *Alcohol Alcohol* 44:20-24, 2009
30. Feng J, Lucchinetti E, Ahuja P, et al.: Isoflurane postconditioning prevents opening of the mitochondrial permeability transition pore through inhibition of glycogen synthase kinase 3 $\beta$ . *Anesthesiology* 103:987-995, 2005
31. Pagel PS: Postconditioning by volatile anesthetics: salvaging ischemic myocardium at reperfusion by activation of prosurvival signaling. *J Cardiothorac Vasc Anesth* 22:753-765, 2008
32. Inamura Y, Miyamae M, Sugioka S, et al.: Aprotinin abolishes sevoflurane postconditioning by inhibiting nitric oxide production and phosphorylation of protein kinase C- $\delta$  and glycogen synthase kinase 3 $\beta$ . *Anesthesiology* 111:1036-1043, 2009
33. U.S. National Institutes of Health: Guide for the Care and Use of Laboratory Animals. U.S. National Institutes of Health No. 85-2. Bethesda, MD, U.S. National Institutes of Health, 1996

34. Hausenloy DJ, Tsang A, Mocanu MM, et al.: Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. *Am J Physiol Heart Circ Physiol* 288:H971-976, 2005
35. Liu YB, Yu B, Li SF, et al.: Mechanisms mediating the cardioprotective effects of rapamycin in ischaemia-reperfusion injury. *Clin Exp Pharmacol Physiol* 38:77-83, 2011
36. Fishbein MC, Meerbaum S, Rit J, et al.: Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. *Am Heart J* 101:593-600, 1981
37. Onishi A, Miyamae M, Kaneda K, et al.: Direct evidence for inhibition of mitochondrial permeability transition pore opening by sevoflurane preconditioning in cardiomyocytes: Comparison with cyclosporine A. *Eur J Pharmacol* 675:40-46, 2012
38. Otani H, Okada T, Fujiwara H, et al.: Combined pharmacological preconditioning with a G-protein-coupled receptor agonist, a mitochondrial KATP channel opener and a nitric oxide donor mimics ischaemic preconditioning. *Clin Exp Pharmacol Physiol* 30:684-693, 2003
39. Kowaltowski AJ, Castilho RF, Vercesi AE: Mitochondrial permeability transition and oxidative stress. *FEBS Lett* 495:12-15, 2001
40. Weiss JN, Korge P, Honda HM, et al.: Role of the mitochondrial permeability transition in myocardial disease. *Circ Res* 93:292-301, 2003
41. Khan S, Salloum F, Das A, et al.: Rapamycin confers preconditioning-like protection against ischemia-reperfusion injury in isolated mouse heart and cardiomyocytes. *J Mol Cell Cardiol* 41:256-264, 2006

42. Vigneron F, Dos Santos P, Lemoine S, et al.: GSK-3 $\beta$  at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways. *Cardiovasc Res* 90:49-56, 2011
43. Gurusamy N, Lekli I, Mukherjee S, et al.: Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway. *Cardiovasc Res* 86:103-112, 2010
44. Hong-Brown LQ, Brown CR, Navaratnarajah M, et al.: Alcohol-induced modulation of rictor and mTORC2 activity in C2C12 myoblasts. *Alcohol Clin Exp Res* 35:1445-1453, 2011
45. Chalmers S, Nicholls DG: The relationship between free and total calcium concentrations in the matrix of liver and brain mitochondria. *J Biol Chem* 278:19062-19070, 2003
46. Di Lisa F, Bernardi P: Mitochondrial function and myocardial aging. A critical analysis of the role of permeability transition. *Cardiovasc Res* 66:222-232, 2005
47. Krenz M, Baines CP, Yang XM, et al.: Acute ethanol exposure fails to elicit preconditioning-like protection in in situ rabbit hearts because of its continued presence during ischemia. *J Am Coll Cardiol* 37:601-607, 2001

### Figure legends

Figure 1: Schematic illustration of the experimental protocol of this study. All hearts were subjected to 30 min global ischemia followed by 120 min reperfusion. Anesthetic preconditioning was elicited by administration of sevoflurane (2% or 1 MAC) for 10 min with a 10 min washout period. Ethanol-treated animals were initially given 1.25% ethanol in their drinking water for 1 week, 2.5% for 1 week then 5% for 8 weeks. Tissue samples were obtained at 10 min after reperfusion. CTL=control; EtOH=ethanol; SEVO=sevoflurane; LY=LY294002, PI3/Akt inhibitor; Rapa=rapamycin, mammalian target of rapamycin (mTOR) inhibitor.

Figure 2: Infarct size as a percentage of LV in eight groups. Treatment with sevoflurane (1 MAC) and 5 % ethanol for 8 weeks equally reduced infarct size compared with control. The combination of sevoflurane and 5 % ethanol conferred a further reduction of infarct size. This additional cardioprotective effect was abolished by LY294002, but not by rapamycin, in SEVO+EtOH. LY204002 treatment alone did not affect infarct size. Data are presented as mean  $\pm$  SD. # $p$ <0.05 vs. CTL, † $p$ <0.05 vs. EtOH and SEVO

Figure 3: (A, B) Representative western blot of phospho Akt and phospho GSK3 $\beta$  from left ventricular samples acquired at 5 min after reperfusion (n=4 for each group). Expression of phospho Akt and phospho GSK3 $\beta$  was significantly increased in EtOH and SEVO. The combination of ethanol and sevoflurane enhanced this increased expression of phospho GSK3 $\beta$  in EtOH+SEVO. Administration of LY294002 abolished this enhanced expression of phospho GSK3 $\beta$  in EtOH+SEVO. However, administration of rapamycin failed to abolish this

enhanced expression. (C, D) Representative western blot of phospho mTOR and p70s6K from left ventricular samples acquired at 5 min after reperfusion (n=4 for each group). Expression of phospho mTOR and phospho p70s6K was not increased in CTL, EtOH and SEVO. However, the combination of ethanol and sevoflurane increased phospho mTOR and phospho p70s6K. Both LY294002 and rapamycin abolished this enhanced expression of phospho mTOR and p70S6K in EtOH+SEVO.

Densitometric evaluation of four experiments as the *x*-fold increase in average light density (AVI) vs. CTL. The results are presented as the ratio of phosphorylation state to total protein. The average light intensity was multiplied by 100 to facilitate presentation of an *x*-fold increase. Data are mean±SD. \*p<0.05 vs. CTL, #p<0.05 vs. EtOH and SEVO

Figure 4: Representative flow cytometric profile of isolated cardiac mitochondria loaded with calcein showing the effects of calcium on mPTP opening as demonstrated by reductions in mitochondrial calcein fluorescence. (A) Exposure of mitochondria to 50  $\mu\text{M}$   $\text{Ca}^{2+}$ : Reductions in mitochondrial calcein fluorescence were not seen in any groups. (B, C) Exposure of mitochondria to 150 $\mu\text{M}$   $\text{Ca}^{2+}$  induced MPTP opening in CTL. This  $\text{Ca}^{2+}$ -induced reduction in calcein fluorescence was attenuated in EtOH and SEVO. This effect was enhanced in EtOH+SEVO, which was abrogated by treatment with LY, but not rapamycin. (D) Effect of calcium (150 $\mu\text{M}$ ) on MPTP opening as demonstrated by reductions in mitochondrial calcein fluorescence. Mean±SD percent change from control in the presence or absence of LY (15  $\mu\text{M}$ ) and rapamycin (100nM). \*p<0.05 vs. CTL, #p<0.05 vs. EtOH, SEVO, n=4 for each group

Figure 5: Schematic diagram of the preconditioning cardioprotection conferred by ethanol and sevoflurane. Phosphorylation of GSK3 $\beta$  by PI3-Akt or mTOR-p70s6K pathway inhibits MPTP opening. Treatment with ethanol or sevoflurane alone activates the PI3-Akt pathway, but not the mTOR-p70s6K pathway. Simultaneous activation of these two pathways is achieved by the combination of ethanol and sevoflurane, but not by ethanol or sevoflurane alone. This activation of dual pathways enhances GSK3 $\beta$  phosphorylation and elevates the threshold of MPTP opening achieved by ethanol or sevoflurane alone. Rapamycin failed to abolish enhanced cardioprotection by the combination of ethanol and sevoflurane. This may be due to mTOR complex 2 which is rapamycin-insensitive. PI3K = phosphatidylinositol 3-kinase; Akt = protein kinase B; GSK3 $\beta$  = glycogen synthase kinase 3 $\beta$ ; mTOR; mammalian target of rapamycin; p70S6K = 70-KDa ribosomal s6 kinase; MPTP = mitochondrial permeability transition pore.

Figure 1




Figure 2









Figure 3

**A** : GSK3 $\beta$ 

**B : Akt**

# C : mTOR



**D : p70s6K**